Thursday15 |  September 2016

LifeSciences BC 2016 AGM and Sponsors' & Members' Appreciation Luncheon
Date: Thursday, September 15th 2016
Time11:30 to 13:30
Location:  Terminal City Club - 837 West Hastings Street, Vancouver
Please note that the AGM is free to attend; however, it's strictly limited to members and sponsors only. After the AGM has concluded, LifeSciences BC is pleased to welcome members, sponsors and non-members to our Sponsors' & Members'
Appreciation Luncheon is free for members and sponsors

LifeSciences BC McCarthy Spotlight Speaking Series on "Leading Small Teams"
September 22, 2016

LifeSciences BC is pleased to feature the Sauder School of Business, STEMCELL Technologies Inc., AbCellera at our McCarthy Spotlight Speaking Event on
Leading Small Teams  

Event Topic: How to successfully manage and lead small teams or groups, whether in the context of a biotech start-up or within a larger life sciences organization.
Sub-Topics Covered:
*    Theoretical approaches and key principles of leadership from a corporate perspective; presentation by Dr. Michael Daniels, Assistant Professor, Organizational Behaviour & Human Resources, Sauder School of Business, UBC.
*    How to successfully choose your business leaders, how to assign roles for key individuals within your life science business and how to successfully transition from founder and scientist to CEO; presentation by Carl Hansen, CEO of AbCellera;
*    Successful leadership of (small) teams/groups at any level within a large life science enterprise; presentation by Kim Lucas, Director of Sales, Americas at STEMCELL Technologies Inc.

Event Details

Date: September 22, 2016
Time: 4:30 - 7:30 PM
Location: Terminal City Club, 837 West Hastings, Vancouver
For Information Contact:
Sarah Wuertz, Manager, Operations & Events
LifeSciences BC
Phone: 604-669-9909 Ext. 104


Access to Innovation
November 2 & 3, 2016

Hosted for its second year, LifeSciences BC's Access to Innovation Conference will bring together health and life sciences stakeholders to present, discuss and deliver meaningful ways to culitivate collaboration, develop and deliver innovation, while improving outcomes and saving healthcare cost.

Confirmed Presenters: Dr. Jane Aubin, Dr. Robert McMaster, Dr. Brendan Byrne, Dr. David Castle, Dr. Heather Davidson, Dr. Bettina Hamelin, Dr. Simon Sutcliffe


 DelMar Pharmaceuticals Presents Data Supporting the Potential of VAL-083 as a New Treatment for Ovarian Cancer at the 11th Biennial Ovarian Cancer Research Symposium

DelMar to work with advisors to confirm a clinical strategy with VAL-083 for the treatment of refractory ovarian cancer, either as a single-agent or in combination with other approved agents.

Arbutus' Chief Scientific Officer, Dr. Michael J. Sofia, Awarded the 2016 Lasker~DeBakey Clinical Medical Research Award

VANCOUVER, British Columbia and DOYLESTOWN, Pa., Sept. 13, 2016 (GLOBE NEWSWIRE) - Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Michael J. Sofia, Arbutus' Chief Scientific Officer, has been awarded the 2016 Lasker~DeBakey Clinical Medical Research Award for the development of a revolutionary treatment of hepatitis C virus (HCV).

 The Centre for Drug Research and Development Launches New Company Developing Life-Saving Sepsis Diagnostic
Vancouver, BC - September 13, 2016: Marking World Sepsis Day, The Centre for Drug Research and Development (CDRD) announces the spin-off of a new company, Sepset Biosciences Inc.

VANCOUVER, CANADA / September 8, 2016 - Biolux Research, developer of OrthoPulse®, is pleased to announce the renewal of its partnership with the Schulman Study Group in an agreement to promote and provide innovative photobiomodulation products to Schulman orthodontic practices and patients.

Xenon Pharmaceuticals Announces Exercise in Full of Option to Purchase Additional Shares and Closing of $34.5 Million Public Offering

BURNABY, British Columbia, Sept. 13, 2016 (GLOBE NEWSWIRE) - Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that the underwriters of the previously announced public offering of its common shares have exercised in full their option to purchase an additional 600,000 common shares, consisting of 450,000 common shares from Xenon and 150,000 common shares from the selling securityholders named in the final prospectus supplement for the offering. The closing of the sale of all common shares occurred today.

Aequus Closes Financing for Gross Proceeds of C$2,743,920

Vancouver, BC. September 13, 2016 - Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, is pleased to announce that it has closed its previously announced offering (the "Offering") of common shares of the Company (the "Shares").

Zymeworks Doses First Patient in Phase 1 Trial of ZW25, a Novel Bi-Specific Antibody for the Treatment of HER2-Expressing Cancers 
Vancouver, Canada (September 15, 2016) - Zymeworks Inc., a biopharmaceutical company discovering and developing innovative multi-functional protein-based therapeutics, including bi-specific antibodies and drug conjugates for the treatment of cancer, announced today that the first patient was dosed in a Phase 1 clinical trial of ZW25 for treatment of HER2-expressing tumors.



With Takeda's $20B deal ceiling, Pharma M&A is even hotter than we knew

Sep 14, 2016 | by Tracy Staton | A who's who of big pharma and biotech companies are out there shopping deals. And now, word has it, Japan's Takeda is breaking with recent tradition to elbow into the fray. 

Merck, Pfizer vaccines ready for their close-up after Clinton's pneumonia diagnosis

Sep 14, 2016  |by Eric Sagonowsky | Hillary Clinton may not be Big Pharma's best friend these days, but her pneumonia diagnosis is lending a hand to vaccines from Merck & Co. and Pfizer.  

Announcing the new president of the National Research Council of Canada
Ottawa, July 28, 2016-The Honourable Kirsty Duncan, Minister of Science, made the following announcement today:

 Merck & Co., Pfizer's experimental diabetes drug ertugliflozin meets main goal of Phase III study

September 15th, 2016 | By: Joe Barber | Merck & Co. and Pfizer on Thursday unveiled Phase III study data illustrating that ertugliflozin met its primary endpoint in the treatment of patients with type 2 diabetes

Acetaminophen product makers told by Health Canada to boost warnings
Consumers to be warned not to mix the pain reliever with alcohol if having 3 or more drinks a day

Sep 15, 2016 | CBC News | Health Canada has told makers of over-the-counter products to provide clearer label instructions and stronger warnings on products containing acetaminophen in an effort to prevent liver damage.

Parkinson's disease protection may begin in the gut 
UI researchers find intestinal cells' immune response protects vital neurons

September 14, 2016| By: Richard C. Lewis, University of Iowa  | 
Your gut may play a pivotal role in preventing the onset of Parkinson's disease. And the reason may be its knack for sleuthing. 

Four basic personality types identified: Pessimistic; optimistic; envious and trusting

September 15, 2016 | Universidad Carlos III de Madrid | A study on human behavior has revealed that 90% of the population can be classified into four basic personality types: Optimistic, Pessimistic, Trusting and Envious. However, the latter of the four types, Envious, is the most common, with 30% compared to 20% for each of the other groups.  
 Competition dates announced for Fall 2016 funding programs
After three months of criss-crossing BC, MSFHR's Research Programs team has completed initial consultations on the Foundation's new suite of funding programs.
Confirmed program launches:
Health Policy Fellowship 
Applications open: week of September 12 
Application deadline: first week of November

Convening & Collaborating Awards 
Applications open: week of September 26 
Application deadline: second week of October

2017 Scholar Program 
Guidelines posted: early September 
Applications open: early October 
Application deadline: TBD (deadline will be posted once confirmed)

For More Information please click here. 
Life Science Career Opportunities

Did you know about our Business Solutions Program? Through our vendor partners, LifeSciences BC members can benefit from significant savings on a number of business services. For the full list of cost savings for members, please see:
Introducing the UPS® Members Benefit Program for Life Sciences BC Members
Take advantage of the UPS Members Benefit Program and save on a variety of UPS services! You'll receive 30% off small package shipments within Canada, to the U.S. and to worldwide destinations, 25% off imports into Canada, discounts starting at 70% off freight shipments and more.  
Save on office supplies and more with Grand & Toy

Through your Life Sciences BC membership, you can save 10%-20% off the web price of wide range of office supplies from Grand & Toy! Plus, there is no charge for next-business-day delivery on orders over $50 to most Canadian locations. (Some conditions apply.) 
Corporate discounts & group rates at The Listel Hotel

The Listel Hotel, a four star boutique hotel, is known for its enthusiastic service and commitment to high design and guest comfort. This intimate Robson street hotel boasts a perfect location with an award-winning restaurant Forage and gastro-pub Timber.
Suite 580 1285 West Broadway, 
Vancouver, BC V6H 3X8